Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Heart Disease and Stroke Cost America Nearly $1 Billion a Day in Medical Costs, Lost Productivity

New Business Pulse Focuses on CDC’s Efforts to Protect American Workers’ Heart Health ATLANTA, GA–(Marketwired – April 29, 2015) – Nearly 800,000 Americans die each year from heart disease, stroke and other cardiovascular diseases, accounting for one in every three deaths. Annually, about one in every six U.S. healthcare dollars is spent on cardiovascular disease. […]

Read More »

Mylan Raises Offer to Acquire Perrigo

POTTERS BAR, England, April 29, 2015 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced that, further to its announcement issued pursuant to Rule 2.5 of the Irish Takeover Rules on April 24, 2015 (the “Rule 2.5 Announcement“), it has increased its offer to acquire the issued and to be issued shares of Perrigo (NYSE: PRGO; TASE).  Under the terms of […]

Read More »

Pfizer cuts full-year forecast on stronger dollar

(Reuters) – U.S. drugmaker Pfizer Inc (PFE.N) cut its full-year revenue and profit forecast, blaming a stronger dollar. However, the drugmaker reported a better-than-expected first-quarter profit, helped by demand for its vaccines and cancer drugs. Pfizer’s shares were roughly unchanged at $34.62 in premarket trade on Tuesday morning. The company, which got 60 percent of […]

Read More »

Strong Merck cancer drug sales upstage rival Bristol-Myers

(Reuters) – Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales. Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales […]

Read More »

Merck shares jump on strong earnings, Januvia safety data

(Reuters) – Merck & Co’s (MRK.N) shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared […]

Read More »

Bristol-Myers tops forecasts, helped by Abilify royalty adjustment

(Reuters) – Bristol-Myers Squibb Co (BMY.N) reported better-than- expected quarterly results, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment. The U.S. drugmaker, whose shares rose 2 percent in premarket trading, on Tuesday said it earned $1.19 billion, or 71 cents per share, in […]

Read More »

Boston Scientific reaches first transvaginal mesh settlement

(Reuters) – Boston Scientific Corp on Tuesday said it reached its first settlement agreement to resolve a portion of the legal claims it faces involving its transvaginal mesh product to treat urinary incontinence. The medical device maker, in a regulatory filing, said it expects to pay about $119 million to resolve 2,970 cases. The Marlborough, […]

Read More »

Progress In Cancer Drug Lifts Merck Earnings, Sending Stock Higher

Like nearly every other company that does any business overseas, pharmaceutical giant Merck saw its revenue take a hit from foreign exchange during the first quarter of 2015. But because the company’s ultimate profit and revenue results were above what Wall Street was expecting to see — and because sales were helped by a promising new […]

Read More »

How Lead Product Dependency Shapes Corporate Strategy In Pharma

A number of recent high-profile events in the pharmaceutical industry have showcased the significance of lead product dependency – that is, the proportion of revenues a company derives from its largest selling drug – on corporate strategy. Indeed, lead product dependency has played an integral role in two recently proposed acquisitions with a combined value […]

Read More »

FDA enters consent decree with Medtronic, Inc.

Company cited for manufacturing violations WEBWIRE – Tuesday, April 28, 2015 The U.S. Food and Drug Administration announced the filing of a consent decree against Medtronic, Inc., and two of the company’s officers—S. Omar Ishrak and Thomas M. Tefft —for repeatedly failing to correct violations, related to the manufacture of Synchromed II Implantable Infusion Pump […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom